GSK has struck a voluntary agreement with the US government to lower the cost of prescription medicines and expand access to ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a 2020 licensing agreement. | GSK is walking away from Ideaya Biosciences after ...

SEOUL, Dec 22 (Reuters) - South Korea's Samsung Biologics (207940.KS) said on Monday it is acquiring its first U.S. drug ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...

Samsung Biologics has agreed to buy GSK's Human Genome Sciences for $280 million, expanding the company's footprint into the U.S. market.

Samsung Biologics America, a subsidiary of Samsing Biologics, a CDMO, has entered into a definitive agreement to acquire 100% ...

GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.

FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK plc has continued its share buyback programme, repurchasing 232,912 ...